The United States Patent and Trademark Office (USPTO) has issued patent US12583840B2 to Orion Corporation. This patent covers a novel method for preparing 2-chloro-4-(1-tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)benzonitrile, an intermediate compound crucial for the synthesis of carboxamide-structured androgen receptor antagonists. The described process specifically utilizes a heterogeneous palladium catalyst.

This patent grant is primarily an intellectual property matter and does not impose new regulatory obligations on drug manufacturers or pharmaceutical companies. However, it signifies a proprietary advancement in the synthesis of specific pharmaceutical intermediates. Companies operating in this space should be aware of this granted patent to ensure they do not infringe on Orion Corporation's intellectual property rights when developing or manufacturing similar compounds.